<DOC>
	<DOCNO>NCT01218997</DOCNO>
	<brief_summary>This Phase 3 multicenter randomize , open-label , safety study assess safety repeat dose Medisorb® naltrexone 380 mg ( VIVITROL® ) administer 1 year adult alcohol and/or opioid dependence define Diagnostic Statistical Manual Mental Health Disorders ( DSM-IV ) criterion . Eligible subject randomize 6:1 ratio receive 1 follow regimen : single intramuscular ( IM ) injection VIVITROL administer every 4 week oral naltrexone 50 mg administer daily .</brief_summary>
	<brief_title>ALK21-006 : Long-Term Study Medisorb® Naltrexone ( VIVITROL® )</brief_title>
	<detailed_description>Safety evaluation include physical examination , electrocardiogram ( ECGs ) , laboratory measure ( include plasma concentration naltrexone 6β-naltrexol ) , assessments injection site , adverse event ( AEs ) . All subject receive psychosocial support study visit duration study , interim telephone contact 2 week monthly visit .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Current diagnosis DSMIV alcohol dependence and/or diagnosis DSMIV opiate dependence within 3 month prior screen 18 year old Desire seek treatment alcohol and/or opiate abuse/dependence Agree use contraception study duration childbearing potential Written inform consent willingness perform study procedure Stable address phone least 1 source contact information ( eg , family member , significant ) Primary Presence opiates urine ( determined urine drug test ) Day 0 prior naltrexone treatment Clinically significant medical/psychological condition abnormality screening ( ie , physical examination , electrocardiogram [ ECG ] , hematology blood chemistry evaluation , urinalysis finding ) Clinically significant active hepatitis hepatic failure evidence 1 following : aspartate transaminase ( AST ) alanine transaminase ( ALT ) high 3 time upper limit normal ( 3xULN ) , hyperbilirubinemia ( bilirubin &gt; 10 % ULN ) , creatine phosphokinase ( CPK ) high 10xULN , prolong prothrombin time ( international normalize ratio ≥1.7 ) , ascites , esophageal variceal disease Manifestation suicidal ideation , psychotic symptom ( include significant violent behavior ) , psychiatric disorder would compromise ability complete study Participation formal methadone program currently within prior 3 year More 2 prior medically supervise detoxification treatment prior 3 year Pregnancy lactation Current prescribe opiate therapy , receipt opiate within 7 day prior study drug dosing , ongoing medical condition likely require prescribed opiate therapy study period Failed naloxone challenge Day 0 ( challenge could repeat 2 time , least 24 hour attempt ) Participation clinical trial within 30 day screen Previous enrollment VIVITROL clinical trial Receipt drug product administer gluteal injection within 180 day prior Day 0 anticipate need gluteal injection study period Intolerance and/or hypersensitivity naltrexone , naloxone , polylactidecopolymers polylactidecoglycolide ( PLG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol dependence</keyword>
</DOC>